Related Experiment Video
Updated: Aug 6, 2026
Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
A new ABCB11 mutation in two Italian children with familial intrahepatic cholestasis
Valerio Nobili1, Silvia Di Giandomenico, Paola Francalanci
1Hepatology, IRCCS Bambino Gesù Hospital, Piazza S. Onofrio, 4-00165, Rome, Italy.
Insights
A new denaturing high-performance liquid chromatography (DHPLC) method aids in diagnosing Progressive Familial Intrahepatic Cholestasis (PFIC). This technique helps identify genetic mutations, improving molecular diagnosis for affected families.
Area of Science:
- Genetics
- Hepatology
- Molecular Biology
Background:
- Progressive Familial Intrahepatic Cholestasis (PFIC) involves defects in bile acid transporters.
- Three genes (ATP8B1, ABCB11, ABCB4) are linked to PFIC, but genotype-phenotype correlations are unclear, complicating gene testing prioritization.
Observation:
- A novel denaturing high-performance liquid chromatography (DHPLC) method was developed to screen for mutations in ATP8B1 and ABCB11.
- This method was combined with genetic analyses and immunolabeling of ABCB11 and ABCB4 gene products in liver specimens.
Findings:
- The DHPLC approach confirmed the clinical diagnosis in two Italian sisters with PFIC.
- A novel missense mutation in the ABCB11 gene was identified in these patients.
Implications:
- This study presents an effective method for detecting the molecular basis of PFIC.
- The findings are expected to facilitate the identification of causative mutations in families affected by PFIC, aiding in diagnosis and potentially guiding future treatments.
Abstract:
Progressive familial intrahepatic cholestasis (PFIC) syndromes are characterized by defects in transporters of conjugated bile acids into the bile canaliculus. Three genes (ATP8B1, ABCB11, ABCB4) are associated with the different forms, but no easy genotype-phenotype correlations help in the prioritization for gene testing. We developed a denaturing high-performance liquid chromatography (DHPLC) method to screen patients with PFIC for mutations in ATP8B1 and ABCB11, and combined genetic analyses with immunolabeling in liver for the ABCB11 and ABCB4 gene products. Used in combination with commercially available antibodies on liver specimens, the DHPLC approach allowed us to confirm the clinical diagnosis in two Italian sisters and to identify a novel missesnse mutation in ABCB11. Our findings are expected to facilitate detection of the molecular cause of PFIC in affected families.
